Acute hepatitis B in a healthcare worker: A case report of genuine vaccination failure

Journal of Hepatology

Volumn 50, Issue 2, 2009, Pages 426-431

  Boot, Hein J ^a   van der Waaij, Laurens A ^b   Schirm, Jurjen ^c   Kallenberg, Cees G M ^d   van Steenbergen, Jim ^a   Wolters, Bert ^e  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c Laboratory for Infectious Diseases   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Municipal Health Service   (Netherlands)

Author keywords

HBV Genotype A; Healthcare worker; Hepatitis B surface antigen (HBsAg); Hepatitis B Virus; Vaccination failure; Waning immunity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANOREXIGENIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DNA VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEMBRANE PROTEIN; RECOMBINANT VACCINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; DNA DETERMINATION; ENZYME ACTIVITY; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; IMMUNE RESPONSE; JAUNDICE; MALE; NAUSEA; PHYLOGENY; PRIORITY JOURNAL; SEROLOGY; UPPER ABDOMINAL PAIN; VACCINE FAILURE; VIRUS STRAIN;

ACUTE DISEASE; HEALTH PERSONNEL; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; VACCINATION;

EID: 58149299651     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.040     Document Type: Article

References (29)

1. Chien Y.C., Jan C.F., Kuo H.S., and Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 28 (2006) 126-135
2. Mast E., Mahoney F.J., Kane M., and Margolis H. Hepatitis B vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (2004), W.B. Saunders Company, Philadelphia 299-337
3. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-565.
4. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 55 (2006) 1-33
5. WHO. Hepatitis B vaccines. Wkly Epidemiol Rec 2004;79:255-263.
6. Fisman D.N., Agrawal D., and Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 35 (2002) 1368-1375
7. De Silvestri A., Pasi A., Martinetti M., Belloni C., Tinelli C., Rondini G., et al. Family study of non-responsiveness to hepatitis B vaccine confirms the importance of HLA class III C4A locus. Genes Immun 2 (2001) 367-372
8. Zuckerman J.N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78 (2006) 169-177
9. Spijkerman I.J., van Doorn L.J., Janssen M.H., Wijkmans C.J., Bilkert-Mooiman M.A., Coutinho R.A., et al. Transmission of hepatitis B virus from a surgeon to his patients during high-risk and low-risk surgical procedures during 4 years. Infect Control Hosp Epidemiol 23 (2002) 306-312
10. Craven D.E., Awdeh Z.L., Kunches L.M., Yunis E.J., Dienstag J.L., Werner B.G., et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 105 (1986) 356-360
11. van Houdt R., Bruisten S.M., Koedijk F.D., Dukers N.H., Op de Coul E.L., Mostert M.C., et al. Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey. J Med Virol 79 (2007) 895-901
12. Banatvala J.E., and Van Damme P. Hepatitis B vaccine - do we need boosters?. J Viral Hepat 10 (2003) 1-6
13. Boddicker J.D., Rota P.A., Kreman T., Wangeman A., Lowe L., Hummel K.B., et al. Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens. J Clin Microbiol 45 (2007) 2902-2908
14. Carman W.F., Zanetti A.R., Karayiannis P., Waters J., Manzillo G., Tanzi E., et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336 (1990) 325-329
15. Protzer-Knolle U., Naumann U., Bartenschlager R., Berg T., Hopf U., Meyer zum Buschenfelde K.H., et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27 (1998) 254-263
16. Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 78 Suppl.1 (2006) S43-S47
17. Yamamoto K., Horikita M., Tsuda F., Itoh K., Akahane Y., Yotsumoto S., et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 68 (1994) 2671-2676
18. Levicnik-Stezinar S. Hepatitis B surface antigen escape mutant in a first time blood donor potentially missed by a routine screening assay. Clin Lab 50 (2004) 49-51
19. Perez-Olmeda M., Nunez M., Garcia-Samaniego J., Rios P., Gonzalez-Lahoz J., and Soriano V. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. AIDS Res Hum Retroviruses 19 (2003) 657-659
20. Koibuchi T., Hitani A., Nakamura T., Nojiri N., Nakajima K., Jyuji T., et al. Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. J Med Virol 64 (2001) 435-440
21. Jilg W., Schmidt M., Deinhardt F., and Zachoval R. Hepatitis B vaccination: how long does protection last?. Lancet 2 (1984) 458
22. Young B.W., Lee S.S., Lim W.L., and Yeoh E.K. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 10 (2003) 23-30
23. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., and McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis 175 (1997) 674-677
24. Lin Y.C., Chang M.H., Ni Y.H., Hsu H.Y., and Chen D.S. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 187 (2003) 134-138
25. Lee P.I., Lee C.Y., Huang L.M., and Chang M.H. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 126 (1995) 716-721
26. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303 (1980) 833-841
27. Ayerbe M.C., and Perez-Rivilla A. Assessment of long-term efficacy of hepatitis B vaccine. Eur J Epidemiol 17 (2001) 150-156
28. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 142 (2005) 333-341
29. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315 (1986) 209-214